TrialJournal of hematology & oncology2024

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.

Jie Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.